Tyra Biosciences (TYRA) reported a third-quarter 2026 net loss of $51.1 million, compared with a $29.9 million loss a year earlier. Net loss per share was $0.74, versus $0.50 in the prior-year quarter.
The clinical-stage biotechnology company ended September with $700.5 million in cash, cash equivalents and marketable securities after completing a roughly $400 million financing. TYRA said its current financial resources are expected to fund planned operations through 2030.
- R&D expense was $43.1 million in the third quarter, up from $25.5 million a year earlier.
- G&A expense was $11.7 million, compared with $7.5 million in the prior-year period.
- Initial Phase 2 SURF302 results showed a 79% overall response rate at 60 mg once daily among 14 participants with single and multiple marker lesions.
- TYRA expects additional Phase 2 results and planned Phase 3 adjuvant study initiation for dabogratinib in 2027.
$TYRA Insider Trading Activity
$TYRA insiders have traded $TYRA stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TYRA stock by insiders over the last 6 months:
- REHAN VERJEE purchased 971 shares for an estimated $20,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TYRA Hedge Fund Activity
We have seen 93 institutional investors add shares of $TYRA stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,796,506 shares (+182.2%) to their portfolio in Q2 2026, for an estimated $57,380,401
- FMR LLC added 1,172,865 shares (+15.1%) to their portfolio in Q2 2026, for an estimated $37,461,308
- DEERFIELD MANAGEMENT COMPANY, L.P. added 1,017,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $32,482,980
- HOOD RIVER CAPITAL MANAGEMENT LLC added 1,016,775 shares (+inf%) to their portfolio in Q2 2026, for an estimated $32,475,793
- LOGOS GLOBAL MANAGEMENT LP removed 850,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $27,149,000
- BLACKROCK, INC. added 814,043 shares (+36.7%) to their portfolio in Q2 2026, for an estimated $26,000,533
- SIREN, L.L.C. added 725,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $23,156,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
